HK1219281A1 - β抑制劑組合物及其用途 - Google Patents

β抑制劑組合物及其用途

Info

Publication number
HK1219281A1
HK1219281A1 HK16107308.4A HK16107308A HK1219281A1 HK 1219281 A1 HK1219281 A1 HK 1219281A1 HK 16107308 A HK16107308 A HK 16107308A HK 1219281 A1 HK1219281 A1 HK 1219281A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor composition
1beta
1beta inhibitor
composition
inhibitor
Prior art date
Application number
HK16107308.4A
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Alexey Repik
Tao Xu
Vasily Ignatiev
Mikhail Samsonov
Original Assignee
R-Pharm Cjsc (Closed Joint Stock Company)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51354448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219281(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R-Pharm Cjsc (Closed Joint Stock Company) filed Critical R-Pharm Cjsc (Closed Joint Stock Company)
Publication of HK1219281A1 publication Critical patent/HK1219281A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
HK16107308.4A 2013-02-15 2016-06-23 β抑制劑組合物及其用途 HK1219281A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/026349 WO2014126582A1 (en) 2013-02-15 2013-02-15 IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Publications (1)

Publication Number Publication Date
HK1219281A1 true HK1219281A1 (zh) 2017-03-31

Family

ID=51354448

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107308.4A HK1219281A1 (zh) 2013-02-15 2016-06-23 β抑制劑組合物及其用途

Country Status (21)

Country Link
EP (2) EP2956471B1 (zh)
JP (1) JP6225197B2 (zh)
KR (1) KR101989551B1 (zh)
CN (1) CN105431448B (zh)
AU (1) AU2013378122B2 (zh)
BR (1) BR112015019729B1 (zh)
DK (1) DK2956471T3 (zh)
EA (1) EA033269B1 (zh)
FI (1) FI2956471T3 (zh)
HK (1) HK1219281A1 (zh)
IL (1) IL240553B (zh)
LT (1) LT2956471T (zh)
MX (1) MX2015010438A (zh)
NZ (1) NZ710900A (zh)
PH (1) PH12015501796A1 (zh)
PL (1) PL2956471T3 (zh)
PT (1) PT2956471T (zh)
RS (1) RS65559B1 (zh)
SG (1) SG11201506389YA (zh)
SI (1) SI2956471T1 (zh)
WO (1) WO2014126582A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506389YA (en) 2013-02-15 2015-09-29 Pharm Cjsc Closed Joint Stock Company R IL-1β INHIBITOR COMPOSITION AND USE THEREOF
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
EP3638700A4 (en) 2017-06-14 2021-04-21 Dingfu Biotarget Co., Ltd PROTEINOUS HETERODIMER AND USE OF IT
WO2019067639A1 (en) 2017-09-26 2019-04-04 Regeneron Pharmaceuticals, Inc. TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN
EP4153613A4 (en) * 2020-05-22 2024-01-24 R-Pharm Overseas, Inc. IL-1-R1 DERIVED INHIBITOR OF IL-1B AND ITS USE
KR20220014531A (ko) * 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
SI2314623T1 (sl) * 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
DK2235064T3 (en) * 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
MX342135B (es) * 2011-03-17 2016-09-14 Ramot At Tel-Aviv Univ Ltd Anticuerpos asimetricos, biespecificos y monoespecificos, y metodos para generar los mismos.
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
SG11201506389YA (en) 2013-02-15 2015-09-29 Pharm Cjsc Closed Joint Stock Company R IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Also Published As

Publication number Publication date
EP2956471B1 (en) 2024-04-10
EA201500842A1 (ru) 2016-02-29
KR101989551B1 (ko) 2019-09-30
PL2956471T3 (pl) 2024-06-24
IL240553A0 (en) 2015-10-29
BR112015019729A2 (pt) 2017-07-18
MX2015010438A (es) 2016-05-05
PH12015501796B1 (en) 2015-11-09
EP4050019A1 (en) 2022-08-31
EP2956471A4 (en) 2019-11-13
PH12015501796A1 (en) 2015-11-09
EA033269B1 (ru) 2019-09-30
JP2016513106A (ja) 2016-05-12
DK2956471T3 (da) 2024-05-21
BR112015019729B1 (pt) 2023-01-24
WO2014126582A1 (en) 2014-08-21
FI2956471T3 (fi) 2024-05-13
AU2013378122A1 (en) 2015-08-27
JP6225197B2 (ja) 2017-11-01
RS65559B1 (sr) 2024-06-28
CN105431448A (zh) 2016-03-23
EP2956471A1 (en) 2015-12-23
IL240553B (en) 2021-02-28
KR20160048028A (ko) 2016-05-03
AU2013378122B2 (en) 2019-05-02
CN105431448B (zh) 2019-08-27
SG11201506389YA (en) 2015-09-29
PT2956471T (pt) 2024-05-27
NZ710900A (en) 2019-09-27
LT2956471T (lt) 2024-06-10
SI2956471T1 (sl) 2024-06-28

Similar Documents

Publication Publication Date Title
HK1223975A1 (zh) 含納米氣泡的組合物及其用途
HK1223089A1 (zh) 激酶抑制劑及其用途
IL246221B (en) Endazoles and their uses
GB201317286D0 (en) Composition and Use
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
GB201305277D0 (en) Novel combination and use
HK1219281A1 (zh) β抑制劑組合物及其用途
GB201321693D0 (en) Composition and uses thereof
GB2519982B (en) Fungicidal composition and the use thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
HK1215657A1 (zh) 抗微生物組合物及相關使用方法
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
GB2516838B (en) Fungicidal compositions and their use
GB201301979D0 (en) New composition and use thereof
GB201322892D0 (en) Surface and composition
GB201318151D0 (en) Composition and device
FR3007291B1 (fr) Composition cicatrisante et utlisation
LT3024825T (lt) Imidazolo karboksamidai ir jų panaudojimas kaip faah inhibitorių
GB201322467D0 (en) Composition and use
GB201301022D0 (en) Composition and uses thereof